MedTrace Logo

Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

NCT02307643 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus

Conditions

Interventions

DRUG

MT-1303 Low dose

DRUG

MT-1303 High dose

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Tsutomu Takeuchi, MD · Keio University Hospital

  • Yoshiya Tanaka, MD · University of Occupational and Environmental Health

  • Kazuoki Kondo, MD · Mitsubishi Tanabe Pharma Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307643 on ClinicalTrials.gov